BioClinica and CCBR-SYNARC have signed an agreement to merge their companies
BioClinica and CCBR-SYNARC have signed an agreement to merge their companies, with the combined company offering four highly specialized services to the clinical trials industry. Those services include medical imaging services across multiple therapeutic areas; worldwide network of research centers and sites; consulting services and cardiac safety monitoring services.
Read the full release here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.